These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results

Carlsmed, Inc. (NASDAQ:CARL) on Tuesday posted upbeat third-quarter results.

The company reported quarterly losses of 34 cents per share which beat the analyst consensus estimate of losses of 40 cents per share. The company reported quarterly sales of $21.554 million which beat the analyst consensus estimate of $19.154 million.

Carlsmed raised its FY2026 sales guidance from $74.000 million-$78.000 million to $78.000 million-$80.000 million.

“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”

Carlsmed shares gained 19.5% to trade at $17.58 on Wednesday.

These analysts made changes to their price targets on Carlsmed following earnings announcement.

• BTIG analyst Ryan Zimmerman maintained the stock with a Buy and raised the price target from $24 to $26.
• Needham analyst David Saxon maintained the stock with a Buy and raised the price target from $17 to $22.
• Truist Securities analyst Richard Newitter maintained the stock with a Buy and raised the price target from $20 to $23.

Considering buying CARL stock? Here’s what analysts think:

Photo via Shutterstock